BOTOX AND FILLER CLINIC BUSINESS PLAN
I. Executive Summary
Company Description
The clinic is a physician-supervised cosmetic injectables practice launching in 2026 in a major U.S. market. We operate in the aesthetic medicine sector and deliver fee-for-service treatments including Botox, dermal fillers, and medical‑grade skincare in a professional clinical setting. The leadership team includes a Medical Director and specialized RNs focused on clinical excellence and patient safety. One clear aim: deliver physician-led, clinic-standard aesthetic care.
We serve adult aesthetic patients in the major U.S. market who want medically supervised injectables and clinical skincare. Short-term goals: open the clinic in 2026, establish protocols, and achieve steady monthly capacity. Long-term goals: scale from a small expert team to a large-scale clinical operation by 2030 while maintaining clinical quality and regulatory compliance. Key differentiators: physician oversight, licensed nursing specialists, and a clinical environment tailored to safety and outcomes.
Problem
Adults aged 30–65 seeking aesthetic care face a clear gap: they want natural results delivered under medical oversight but too often find nonclinical settings, unlicensed providers, or one-size-fits-all treatments that produce inconsistent or unsafe outcomes. Key pain points are lack of licensed medical practitioners, limited personalization, safety and efficacy worries, and deferred care due to anxiety and misinformation.
There is an unmet need for a physician-supervised, clinical practice that delivers medical-grade injectables with licensed oversight. Launching in 2026, our clinic fills that gap by providing a Medical Director, specialized RNs, and a fee-for-service menu (Botox, dermal fillers, medical-grade skincare) designed to scale to a large clinical operation by 2030.
Solution
Adults aged 30–65 seeking subtle, natural facial refreshment face a shortage of trusted, medical-grade options that avoid the "overdone" look. We deliver FDA-approved neuromodulators and dermal fillers in a clinical setting, with licensed practitioners and in-depth consultations that produce bespoke treatment plans tailored to each patient’s anatomy and goals.
We prioritize safety and natural results through a clinical environment, licensed staff, and a medical director and specialized nurses starting at launch in 2026; clinical, safety-first injectables that restore youthful appearance and confidence.
Mission Statement
Our mission is to empower individuals to look and feel their best through expert-led, natural-looking aesthetic enhancements that prioritize clinical safety and personalized care. We embrace a less-is-more philosophy that honors each client's unique features and delivers subtle, refreshed outcomes. By combining medical expertise with a bespoke consultative approach, we aim to be the most trusted name in non-surgical rejuvenation.
Key Success Factors
Success rests on clinical leadership, premium positioning, tight operations, and steady demand.
-
Expert-led team: Medical Director at launch; 16 practitioners by 2030.
-
Premium "less is more" brand: attracts high-value, loyal clients.
-
Rapid unit economics: breakeven within two months; 11-month payback.
-
High-margin operations: optimized product costs; senior staff 80% capacity target.
-
Reliable demand engine: strong digital marketing plus referral network.
Financial Summary
Key financial outcomes project rapid breakeven, strong margins, and attractive investor returns.
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
|
|
|
Projected EBITDA |
$620,000 |
$1,762,000 |
$3,603,000 |
Expected ROI |
IRR 18% / ROE 22.9% |
IRR 18% / ROE 22.9% |
IRR 18% / ROE 22.9% |
Financial requirements: Total launch CAPEX $372,000; minimum cash required $757,000 (Apr-26); breakeven Feb-26; payback in 11 months; expected IRR 18% and ROE 22.9%.
Overall outlook: highly profitable, scalable entry into the U.S. medical aesthetics market.
Funding Requirements
We seek $1,129,000 to fund the 2026 launch; the business targets Year 1 EBITDA of $620,000, breakeven by February 2026, an 18% IRR and 22.9% ROE.
Categories |
Amount, USD |
Clinic build-out & renovation |
150,000 |
Medical equipment (treatment chairs & equipment) |
80,000 |
IT systems & software licenses |
30,000 |
Initial product inventory (bulk) |
25,000 |
Other capex (furniture, security, website, signage, sterilization) |
87,000 |
Capital expenditures (total, 2026 launch) |
372,000 |
Working capital (minimum cash position, Apr-26) |
757,000 |
Total funding required |
1,129,000 |